Final Trade Detail
- Inked a deal with Juno Therapeutics with an upfront payment of $25 million and $22 million over the next 5 years. Milestone payments can exceed $230 million
- EDIT has a market cap of $1.5 billion... and easy acquisition target from a major biopharma company
- Stock has traded sideways nearly all year as studies continue to prove the efficacy of gene editing - a revolutionary technology.
It’s one of the greatest scientific inventions ever.
It will create billions of shareholder value over the coming 12-24 months.
You need to be a part of it. Because we believe you will be rewarded handsomely.
You see, Editas (EDIT) is a leader in CRISPR – an incredible gene editing technology.
This technology can literally alter and change our DNA strands. Doctors can use CRISPR technology to “fix” our DNA. It can remove any and all diseases, mutations, or genetic deformities from babies before they’re born. Every child will be perfectly healthy in the future. It’s insane.
Think of the ramifications for longevity of life. Impacts on health care. Social Security. The potential of gene editing is limitless. And so are the knock-on effects.
The studies continue to come out proving the efficacy of this technology. Editas is one of the leaders. It just inked a royalty deal with Juno Therapeutics with hundreds of millions in milestone payments.
Today, you can get in prices almost 30% below its March 2018 high of $45. We think Editas will easily head back to its March 2018 high of $45 at a minimum over the next 12 months – a gain of 40%.
We actually think Editas could double in the next 24 months… that is if it doesn’t get bought before then.